Work with Hareesh Nair | NotedSource
Associate Professor/Research
https://cv.notedsource.io/me/VOR85M6R
Hareesh Nair
Associate Professor/Research
Research Expertise
Reproductive Health and Oncology
Legacy Map
Full ViewPublications
Induction of Aromatase Expression in
Cervical Carcinomas: Effects of Endogenous
Estrogen on Cervical Cancer Cell
Proliferation
Cancer Research
2005
Elevated Expression of the Oncogene
c-fms and Its Ligand, the
Macrophage Colony-Stimulating Factor-1, in
Cervical Cancer and the Role of
Transforming Growth Factor-β1 in Inducing
c-fms Expression
Cancer Research
2007
Overexpression of the Colony-Stimulating
Factor (CSF-1) and/or Its Receptor
c-fms
in Mammary Glands of Transgenic Mice
Results in Hyperplasia and Tumor Formation
Cancer Research
2004
EC359: A First-in-Class Small-Molecule
Inhibitor for Targeting Oncogenic LIFR
Signaling in Triple-Negative Breast Cancer
Molecular Cancer Therapeutics
2019
Progesterone receptor isoforms, agonists
and antagonists differentially reprogram
estrogen signaling
Oncotarget
2017
Targeting LIF/LIFR signaling in cancer
Genes & Diseases
2022
Utilizing cell line-derived organoids to
evaluate the efficacy of a novel
LIFR-inhibitor, EC359 in targeting
pancreatic tumor stroma
Genes & Cancer
2018
Growth inhibitory efficacy of
Cornus�officinalis in a cell culture model
for triple‑negative breast cancer
Oncology Letters
2019
Gossypin as a Novel Selective Dual
Inhibitor of v-raf Murine Sarcoma Viral
Oncogene Homolog B1 and Cyclin-Dependent
Kinase 4 for Melanoma
Molecular Cancer Therapeutics
2013
LIF/LIFR oncogenic signaling is a novel
therapeutic target in endometrial cancer
Cell Death Discovery
2021
LIFR inhibition enhances the therapeutic
efficacy of HDAC inhibitors in triple
negative breast cancer
Communications Biology
2021
The Pleiotropic role, functions and
targeted therapies of LIF/LIFR axis in
cancer: Old spectacles with new insights
Biochimica et Biophysica Acta (BBA) -
Reviews on Cancer
2022
Growth inhibitory efficacy and
anti‑aromatase activity of Tabebuia
avellanedae in a model for post‑menopausal
Luminal A breast cancer
Biomedical Reports
2019
Inhibition of estrogen-induced mammary
tumor formation in MMTV-aromatase
transgenic mice by 4-chlorophenylacetate
Cancer Letters
2007
EC313-a tissue selective SPRM reduces the
growth and proliferation of uterine
fibroids in a human uterine fibroid tissue
xenograft model
Scientific Reports
2019
An efficient model of human endometriosis
by induced unopposed estrogenicity in
baboons
Oncotarget
2016
Abstract P4-13-04: Efficacy of
dipsacus asperoides (DA) in a model
for triple negative breast cancer
Cancer Research
2017
Growth Inhibitory Efficacy of Chinese
Herbs in a Cellular Model for
Triple-Negative Breast Cancer
Pharmaceuticals
2021
Effects of Combination of Estradiol with
Selective Progesterone Receptor Modulators
(SPRMs) on Human Breast Cancer Cells In
Vitro and In Vivo
PLOS ONE
2016
1205Lu Human Metastatic Melanoma Cells,
not Human!
Journal of Cancer Science &
Therapy
2013
Anti-Proliferative and Pro-Apoptotic
Effects Of Dipsacus Asperoides in a
Cellular Model for Triple-Negative Breast
Cancer
Archives of Breast Cancer
2022
Growth inhibitory efficacy of the
nutritional herb
Psoralea corylifolia in a model of
triple‑negative breast cancer
International Journal of Functional
Nutrition
2021
Estradiol prodrugs (EP) for efficient oral
estrogen treatment and abolished effects
on estrogen modulated liver functions
The Journal of Steroid Biochemistry and
Molecular Biology
2017
The LIFR Inhibitor EC359 Effectively
Targets Type II Endometrial Cancer by
Blocking LIF/LIFR Oncogenic Signaling
International Journal of Molecular
Sciences
2023
Abstract P5-14-02: Efficacy of tabebuia
avellandae extract on a cell culture model
for triple negative breast cancer
Cancer Research
2015
Next step in the development of
mesoprogestins: the preclinical profile of
EC313
Frontiers in Endocrinology
2023
Esters of levonorgestrel and etonogestrel
intended as single,
subcutaneous-injection, long-lasting
contraceptives
Steroids
2018
Abstract LB-208: First-in-class steroidal
leukemia inhibitory factor (LIF) inhibitor
in targeted cancer therapy
Cancer Research
2016
A prodrug design for improved oral
absorption and reduced hepatic interaction
Bioorganic & Medicinal
Chemistry
2017
Retraction notice to “Design of
curcumin-loaded PLGA nanoparticles
formulation with enhanced cellular uptake,
and increased bioactivity in vitro and
superior bioavailability in vivo”
[Biochem. Pharmacol. 79 (2010) 330–338]
Biochemical Pharmacology
2016
Approaches in the Chemoprevention of
Breast Cancer
Journal of Cancer Science &
Therapy
2013
Laboratory Opossum (Monodelphis domestica)
Model for Melanoma Chemoprevention
Journal of Cancer Science &
Therapy
2012
Targeting Aldose Reductase: A Novel
Strategy in Treating Endocrine Resistance
Using Combination Therapy.
Cancer Research
2009
Cytotoxic effects of crystal proteins from
Bacillus thuringiensis against
breast cancer cells.
Cancer Research
2009
Pharmacological inhibition of the LIF/LIFR
autocrine loop reveals vulnerability of
ovarian cancer cells to ferroptosis
npj Precision Oncology
2024
Growth Inhibitory Efficacy of Tabebuia
Avellanedae in a Model for Triple Negative
Breast Cancer
Archives of Breast Cancer
2021
Abstract P3-09-04: Growth inhibitory
effects of Cornus officinalis on a model
for triple negative breast cancer
Cancer Research
2016
Abstract 4607: Novel role of PARP4 in
hormone-dependent breast cancer
progression and metastasis
Cancer Research
2010
Discovery and preclinical pharmacology of
EC330: A first-in-class leukemia
inhibitory factor (LIF) inhibitor
European Journal of Cancer
2016
Abstract 1484: Aldose reductase inhibition
prevents breast cancer cell growth and
restores breast cancer cell hormone
dependency
Cancer Research
2010
Novel Cytotoxic Proteins of
Bacillus thuringiensis Isolated
from Peninsular India.
Cancer Research
2009
Nano-gossypin, a novel cdk2/VEGF inhibitor
formulation against breast cancer.
Cancer Research
2009
P-341
Fertility and Sterility
2006
Significance of LIF/LIFR Signaling in the
Progression of Obesity-Driven
Triple-Negative Breast Cancer
Cancers
2024
Abstract PO1-08-09: Drynaria fortunie, a
nutritional herb for prevention in triple
negative breast cancer
Cancer Research
2024
Leukemia Inhibitory Factor (LIF)
SpringerReference
Abstract 5998: Pharmacological inhibition
of the LIF-LIFR autocrine loop reveals
vulnerability of ovarian cancer to
ferroptosis
Cancer Research
2024
Abstract 4688: EC359, A new therapeutic
drug for the treatment of low grade serous
ovarian cancer
Cancer Research
2024
Abstract 5986: Significance of LIF/LIFR
axis in the progression of inflammatory
breast cancer
Cancer Research
2024
4 Therapeutic utility of EC359 for
targeting LIFR signaling in Type II
endometrial cancer
Gynecologic Oncology Reports
2023
Abstract 4966: Targeting LIF/LIFR
autocrine loops with EC359 in ovarian
cancer: A novel LIFR targeted therapy
Cancer Research
2023
Abstract 1756: Targeting LIFR/c-Myc Axis
to Overcome Docetaxel Resistance in
Prostate Cancer
Cancer Research
2023
Abstract 3408: The role of obesity in
promoting the LIF/LIFR signaling in triple
negative breast cancer
Cancer Research
2023
Abstract 1062: Antiproliferative activity
of EC359, an inhibitor of leukemia
inhibitory factor receptor (LIF-R), singly
and in combination with chemotherapy drugs
against pancreatic cancer cell lines
Cancer Research
2022
Abstract P5-10-01: Leukemia inhibitory
factor receptor inhibition reduces obesity
driven progression of triple negative
breast cancer
Cancer Research
2022
Abstract 1253: Therapeutic targeting of
endometrial cancer with novel LIFR
inhibitor EC359
Cancer Research
2021
Abstract 562: Novel combination therapy
for treating TNBC using LIFR and HDAC
Inhibitors
Cancer Research
2020
Abstract LB-B04: Development of a
first-in-class leukemia inhibitory factor
(LIF)/LIFR inhibitor, EC359 for targeted
therapy
Molecular Cancer Therapeutics
2018
Abstract P3-11-08: Targeting LIFR enhances
the activity of HDAC inhibitors for the
treatment of triple negative breast cancer
Cancer Research
2020
Abstract 4716: Therapeutic utility of
EC359 for targeting oncogenic LIFR
signaling in triple negative breast cancer
Cancer Research
2019
Abstract 4316: Targeting LIFR overcomes
HDAC inhibitor resistance in ovarian
cancer
Cancer Research
2019
Abstract P2-06-02: Development of a
first-in-class small molecule inhibitor
(EC359) targeting oncogenic LIF/LIFR
signaling for the treatment of triple
negative breast cancer
Cancer Research
2019
Abstract 5875: Development of LIFR
inhibitor EC359 as a novel therapeutic for
ovarian cancer
Cancer Research
2018
Synthesis and biological evaluation of 11′
imidazolyl antiprogestins and
mesoprogestins
Steroids
2014
Abstract 5792: Development of cell line
derived organoids to evaluate stroma
targeted therapies in pancreatic cancer
Cancer Research
2017
Abstract P3-05-08: Effect of a novel
selective progesterone receptor modulator
EC312 for menopausal hormone therapy (MHT)
in comparison with Bazedoxifene in vitro
Cancer Research
2015
Role of chronic inflammation in diabetic
retinopathy
Inflammation and Regeneration
2013
Abstract 2952: Image-guided miRNA therapy
for metastatic breast cancer
Cancer Research
2012
Progestins/Antiprogestins: Role in
Pathogenesis and Treatment for
Endometriosis
Gynecology & Obstetrics
2012
Reappraisal of Dietary Phytochemicals for
Coronavirus Infection: Focus on Hesperidin
and Quercetin
Antioxidants - Benefits, Sources,
Mechanisms of Action
2021
Inhibition of LIFR Blocks Adiposity-Driven
Endometrioid Endometrial Cancer Growth
Cancers
2022
Modeling sunscreen‐mediated melanoma
prevention in the laboratory opossum (M onodelphis domestica)
Pigment Cell & Melanoma
Research
2014
Synthesis and antiprogestational
properties of novel 17-fluorinated
steroids
Steroids
2013
Increased expression of macrophage
colony–stimulating factor and its receptor
in patients with endometriosis
Fertility and Sterility
2012
Estrogen Receptor-beta Mediates the
Protective Effects of Aromatase Induction
in the MMTV-Her-2/neu x Aromatase Double
Transgenic Mice
Hormones and Cancer
2011
Modeling ductal carcinoma in situ: a
HER2–Notch3 collaboration enables luminal
filling
Oncogene
2011
Estrogen receptor-β activation in
combination with letrozole blocks the
growth of breast cancer tumors resistant
to letrozole therapy
Steroids
2011
Hyaluronic Acid-Bound Letrozole
Nanoparticles Restore Sensitivity to
Letrozole-Resistant Xenograft Tumors in
Mice
Journal of Nanoscience and
Nanotechnology
2011
Delivery of antiinflammatory
nutraceuticals by nanoparticles for the
prevention and treatment of cancer
Biochemical Pharmacology
2010
RETRACTED: Thymoquinone poly
(lactide-co-glycolide) nanoparticles
exhibit enhanced anti-proliferative,
anti-inflammatory, and chemosensitization
potential
Biochemical Pharmacology
2010
Induction of endometrial epithelial cell
invasion and c-fms expression by
transforming growth factor beta
Molecular Human Reproduction
2009
Elevated aromatase expression correlates
with cervical carcinoma progression
Gynecologic Oncology
2009
BU-32: a novel proteasome inhibitor for
breast cancer
Breast Cancer Research
2009
Modeling the early endometriotic lesion:
mesothelium-endometrial cell co-culture
increases endometrial invasion and alters
mesothelial and endometrial gene
transcription
Fertility and Sterility
2008
Modulation of in Situ Estrogen Synthesis
by Proline-, Glutamic Acid-, and
Leucine-Rich Protein-1: Potential Estrogen
Receptor Autocrine Signaling Loop in
Breast Cancer Cells
Molecular Endocrinology
2008
HER-2/neu×aromatase double transgenic mice
model: The effects of aromatase
overexpression on mammary tumorigenesis
The Journal of Steroid Biochemistry and
Molecular Biology
2007
Estrogen receptor alpha is required for
mammary development and the induction of
mammary hyperplasia and epigenetic
alterations in the aromatase transgenic
mice
The Journal of Steroid Biochemistry and
Molecular Biology
2005
Education
Mahatma Gandhi University
PhD, Cancer Biology
Kottayam
Experience
Evestra Inc
Senior Scientist / 2014 — Present
Texas Biomedical Research Institute
Staff Scientist / 2010 — 2012
University of Texas Health Science Center at San Antonio
Assistant Professor / 2003 — 2009
Join Hareesh on NotedSource!
Join Now
At NotedSource, we believe that professors, post-docs, scientists and other researchers have deep, untapped knowledge and expertise that can be leveraged to drive innovation within companies. NotedSource is committed to bridging the gap between academia and industry by providing a platform for collaboration with industry and networking with other researchers.
For industry, NotedSource identifies the right academic experts in 24 hours to help organizations build and grow. With a platform of thousands of knowledgeable PhDs, scientists, and industry experts, NotedSource makes connecting and collaborating easy.
For academic researchers such as professors, post-docs, and Ph.D.s, NotedSource provides tools to discover and connect to your colleagues with messaging and news feeds, in addition to the opportunity to be paid for your collaboration with vetted partners.
Expert Institutions
Proudly trusted by
